Michael King News
-
A new gene-based test for prostate cancer may reduce the need to repeat painful biopsies that can also cause serious infections, according to a study to be published in the Journal of Urology.
-
Barclays Plc recruited a team for its wealth and investment management division from Morgan Stanley Smith Barney that includes former New York Jets wide receiver Wayne Chrebet.
-
Vivus Inc.’s shareholders are poised to reap an 88 percent windfall in a takeover after the company’s weight-loss drug moved one step closer to winning approval to treat America’s 78 million obese adults.
-
Alnylam Pharmaceuticals Inc., the developer of a treatment for a rare genetic disorder, rose the most ever after the drug showed promise in an early clinical trial.
-
Pharmacyclics Inc., the developer of blood cancer treatments with Johnson & Johnson, fell the most since April 10 ahead of Johnson & Johnson earnings scheduled for release tomorrow.
-
A Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Pfizer Inc.’s Viagra, won U.S. regulatory approval.
-
Amylin Pharmaceuticals Inc. is preparing for a second round of bids after attracting offers that value the diabetes drugmaker at $25 to $29 a share, said people with knowledge of the process.
-
Amylin Pharmaceuticals Inc. and Alkermes Plc succeeded in their third attempt to gain U.S. clearance for Bydureon, a once-weekly version of Amylin’s diabetes shot.
-
Amylin Pharmaceuticals Inc., the diabetes drugmaker that has put itself up for sale, received offers from Sanofi and Merck & Co. in an initial round of bidding, said three people familiar with the process.
-
Alnylam Pharmaceuticals Inc. is in talks with “more than one” possible partner to help develop the company’s injectable drug to treat high cholesterol in patients for whom statins aren’t effective, Chief Executive Officer John Maraganore said.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page